• Primary renal PNET was first reported by Seemayer

  2019-07-26

  

  Primary renal PNET was first reported by Seemayer et al in 1975. The possible etiology of rPNET is based on the theory of neural cell intussusception in the kidney during development that initiates the tumorigenesis. rPNET most commonly affects young adults, with a mean age of 30.4 years and male pr

• SGI1776 The optimization of the lead compound was initiated

  2019-07-26

  

  The optimization of the lead compound () was initiated and the initial key SAR and the results of the structural modifications of lead compound are summarized in . Replacement of the carboxylic SGI1776 moiety with other functional groups led to loss of functional activity against EP4 receptor. Alt

• In addition to providing substantial insight into substrate

  2019-07-26

  

  In addition to providing substantial insight into substrate recognition, structural studies have revealed important details about mechanisms of glycosylation and HCF-1 cleavage [28,30,33]. Activation of the nucleotide-sugar is accomplished through interactions of the β-phosphate with the N-terminus

• Importantly MPO is not only

  2019-07-26

  

  Importantly, MPO is not only a marker of cardiovascular disease but also emerges as a critical mediator of vascular inflammatory disease: Liberated MPO binds to the endothelium in a leukocyte-independent manner, is subsequently taken up by the endothelium and transcytoses and accumulates in the sube

• CGRP 8-37 (rat) br No Evidence for Further ET Receptor Subty

  2019-07-26

  

  No Evidence for Further ET-Receptor Subtypes Further receptor subclassifications have been proposed including suggestions that ETB could be subdivided into ETB1, present on endothelial cells, and ETB2 on smooth muscle cells, but there currently is no evidence that the receptors expressed by these

• The most significant finding was

  2019-07-26

  

  The most significant finding was the inhibition of EROD and BFCOD activity by CLO. Inhibition of EROD and BFCOD were reversible, as pre-incubation did not enhance CLO inhibitory potency, and no reductions in IC50 values were observed. We further characterized the kinetic pattern of inhibition using

• A prominent example of such enzyme is the proteasome

  2019-07-25

  

  A prominent example of such enzyme is the proteasome, a highly promising target not only in cancer, but also in inflammatory and autoimmune diseases. Circulating proteasomes and respective anti-proteasome autoantibodies were detected in serum samples from patients with autoimmune diseases such as mu

• br Methods br Results br Discussion Skin

  2019-07-25

  

  Methods Results Discussion Skin biopsy and microneurography have both been described as useful tools in the diagnosis of PAN, directly identifying peripheral sympathetic fibers without the mediation of specific GS967 where organs (Donadio et al., 2005, Donadio et al., 2012a, Donadio and Li

• Regarding their reported beneficial properties

  2019-07-25

  

  Regarding their reported beneficial properties on the digestive tract, the aim of this study was to evaluate the effect of water extracts of three Hypericum sps., HP, HA, HU and some of the main phenolic compounds (Ch, R and Q) on DNA protection against oxidative and alkylating DNA damage induced by

• br Molecular modeling study Molecular

  2019-07-25

  

  Molecular modeling study Molecular modeling study was essentially needed to understand and interpret the DHFR inhibitory pattern of this new class of compounds. Computational docking is an algorithm designed to estimate two main terms. The first is to determine the suitable position and the orien

• br Four active site residues of

  2019-07-25

  

  Four active site residues of Δ1-KSTD1 are fully conserved in Δ1-KSTDs from different species (Supplementary Figure S2). These residues are Tyr-119, Tyr-487, and Gly-491 from the FAD-binding domain and Tyr-318 from the catalytic domain. The structure of the Δ1-KSTD1•ADD complex revealed that the hy

• br Funding This work was supported by grants to

  2019-07-25

  

  Funding This work was supported by grants to A.S. from the Swedish Cancer Foundation, Sweden (Grant number: CAN, 2015/637), the Swedish Medical Council, Sweden (Grant number: 2017- 01274), the Foundations at Skåne University Hospital, Sweden and to KB, SRS, NC, BCS, and SS from the Royal Physiogr

• br Conclusion In vivo pharmacokinetic

  2019-07-25

  

  Conclusion In vivo pharmacokinetic studies showed that dasatinib monohydrate pretreatment significantly decreased the blood level of CsA in rats, which was most probably due to the induction of CYP3A2 isoenzymes. The nilotinib pre-treatment had no significant effects on cyclosporine pharmacokinet

• Epigallocatechin DDI is one of the main problems with

  2019-07-25

  

  DDI is one of the main problems with serious clinical consequences in clinical settings. Several reports have highlighted the role of modulation of drug-metabolizing enzymes, especially CYP450 s, as a major mechanism involved in clinical DDIs [3,4,7]. The present study aimed to investigate the effec

• br Materials and methods br

  2019-07-25

  

  Materials and methods Results and discussion Conclusions Conflict of interest Acknowledgments This work was financially supported by the National Natural Science Foundation of China (31302162, 31171762), National High Technology Research and Development Program of China (863 Program,

15317 records 971/1022 page Previous Next First page 上5页 971972973974975 下5页 Last page